Imperative Care has reported results from a post-hoc analysis of the SYMPHONY-PE trial, assessing the role of early mechanical thrombectomy in patients diagnosed with intermediate-risk pulmonary embolism (PE).
Published in Circulation: Cardiovascular Interventions, the analysis reviewed outcomes for patients treated using the Symphony thrombectomy system and compared heart recovery measures between those treated within 12 hours of diagnosis and those treated later.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Published data suggest that performing thrombectomy within 12 hours may lead to greater short-term improvements in right ventricular function and pulmonary artery pressure compared with procedures done after 12 hours.
Patients were divided into early and late treatment groups, with early intervention defined as less than 12 hours after diagnostic imaging. Out of 109 participants, 48 received early treatment, accounting for 44% of the trial population.
Average pulmonary artery pressure fell by 8.6 in the early group compared with 5.8 in the late group, a difference the analysis states reached nominal statistical significance.
Reduction in the right ventricle-to-left ventricle (RV/LV) ratio from baseline to 48 hours was 0.52 for early treatment compared to 0.37 for late intervention.
The difference in efficacy outcomes was reported to be most pronounced in higher-risk cases, as assessed by the composite pulmonary embolism shock score (CPES).
On safety, the results indicated no significant difference in major adverse events between the two groups within 48 hours after the procedure.
One major adverse event was reported in the early group, with none in the late group. The analysis recorded no device-related serious adverse events or deaths in either group.
Imperative Care chairman and CEO Fred Khosravi said: “We set out to establish a new standard in PE treatment by developing a large-bore system that removes the guesswork from thrombectomy and is designed to enable more efficient procedures and real-time decision-making so physicians can focus on what matters most: the patient.
“Now, with more than 500 PE patients treated since commercial launch, we are encouraged by the growing physician confidence in Symphony and the continued clinical evidence supporting its procedural efficiency and favourable safety profile.”
The Symphony thrombectomy system gained US Food and Drug Administration (FDA) clearance in August 2025, supported by data from the company’s multi-site IDE study, which formed the basis for this latest analysis.
In March 2026, Imperative Care enrolled the first patient in its prospective, observational CLEAR-IT study aimed at assessing the performance of the Symphony and Prodigy thrombectomy systems.
